On 7 September 2019, in partnership with the Wuxi Government, AstraZeneca celebrated the official opening of theWuxi国际生命科学创新校园(I·Campus)and marked the signing of the first partners and initial 10 companies to join the campus.
Situated in the Wuxi National High-tech District in Jiangsu, China,I·Campus brings together innovative 4D (Drug, Device, Diagnosis and Digital) companies, government, and medical and academic institutions together via an open collaboration platform, helping to accelerate healthcare innovation and sciences in China.
我·校园：开放大量的机会来改善患者的结果
I·Campus is a priority for the local Wuxi Government, and is predicted to attract more than 50 innovative companies over the next three years. AstraZeneca’s experiences in China, and its otherfive iDREAM hubsacross Emerging Markets, have helped to develop the pioneering Wuxi concept.
阿斯利康（Astrazeneca）凭借野心建立一个跨大陆，跨行业生物群岛的网络，致力于使我们的市场更加紧密，从而为全球各地的人们带来好处，并为社会带来价值。欧洲杯微信买球
Our new partners
开幕式的标志是将第一组合作伙伴签署到I·校园，包括英国生物工业协会（BIA），印度全国软件和服务公司协会（NASSCOM），俄罗斯Skolkovo科学与技术研究所和中国香港创新医疗协会。
The first 10 companies joining the I·Campus were also announced – they include Japanese medical equipment company Omron, Chinese clinical trial company Tigermed, British early cancer screening company Abcodia, British medical device company ClearSky, Chinese Hong Kong oncogene test company Sanomics, Russian natural linguistic analysis company Semantic Hub, Chinese Taiwan medicine transmission platform company HCmed, and Indian healthcare AI company Tricog.
有了这个新的枢纽，用于吸引顶级国内和海外人才，以及在AI和大数据等尖端领域的投资和进步，I·校园有望成为Wuxi国际生活科学集群的跳动。
欧洲杯微信买球阿斯利康的Wuxi故事：为医疗创新的新时代奠定基础
AstraZeneca’s Wuxi innovation story began back in 2017 with the creation of the Healthcare Internet of Things Innovation Center, established to explore innovative new treatment options and to seek out opportunities for integrating digital solutions into the patient journey. In 2018, AstraZeneca set out to build a global innovative sciences network – the first implementation of its incubation initiative on the Chinese mainland.
Earlier this year, at the 2019 Boao Forum, Asia Annual Conference, in partnership with the Wuxi municipal government, AstraZeneca announced the development of thisWuxi国际生命科学创新校园(I·Campus), with an aim to nurture innovation and create a world-class healthcare innovation ecosystem.
The official launch of I·Campus is a defining moment, uniting stakeholders from around the world to confront challenges to pharmaceuticals and diagnostics, as well as digitalisation and technology.
AstraZeneca has always regarded Wuxi as an important base for developing patient-centric innovation and strategy in China. I·Campus, together with our Healthcare Internet of Things Innovation Center, will draw on industry insights – taken from our rich experience in China – to develop a truly world-class, life sciences ecosystem.